Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
1.730
+0.030 (1.76%)
At close: Nov 13, 2026, 4:00 PM EST
1.760
+0.030 (1.73%)
After-hours: Nov 13, 2026, 7:30 PM EST
Voyager Therapeutics Employees
Voyager Therapeutics had 141 employees as of December 31, 2025. The number of employees decreased by 31 or 18.02% compared to the previous year. That makes Voyager Therapeutics the 29,338th largest employer in the world and 3,712th in the United States.
Employees
141
Change (1Y)
-31
Growth (1Y)
-18.02%
Revenue / Employee
$178,071
Profits / Employee
-$741,348
Market Cap
107.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 141 | -31 | -18.02% | 141 | 0 |
| Dec 31, 2024 | 172 | 10 | 6.17% | 172 | 0 |
| Dec 31, 2023 | 162 | 37 | 29.60% | 162 | 0 |
| Dec 31, 2022 | 125 | 24 | 23.76% | 125 | 0 |
| Dec 31, 2021 | 101 | -78 | -43.58% | 101 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 134 |
| Adagene | 128 |
| Immunic | 100 |
| OnKure Therapeutics | 45 |
| NovaBridge Biosciences | 30 |
| Cue Biopharma | 29 |
| Unicycive Therapeutics | 22 |
| Outlook Therapeutics | 17 |
VYGR News
- 5 days ago - Voyager Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 9 days ago - Voyager Therapeutics price target lowered to $12 from $18 at Baird - TheFly
- 9 days ago - Voyager Therapeutics reports Q3 EPS (40c), consensus (42c) - TheFly
- 10 days ago - Voyager Therapeutics Quarterly report: Q3 2026 - Filings
- 10 days ago - Voyager Therapeutics Earnings release: Q3 2026 - Filings
- 19 days ago - Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 - GlobeNewsWire
- 25 days ago - Voyager Therapeutic CEO Alfred Sandrock to depart, Robin Swartz to succeed - TheFly
- 25 days ago - Voyager Announces CEO Succession Plan, Appoints Robin Swartz President - GlobeNewsWire